# Uncovering the Potential Mechanisms of Ergothioneine in Neuroinflammation Through Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and In Vitro Validation

**Authors:** Deyou Cao, Jingxuan Jia, Yishu Yin, Weihong Lu

PMC · DOI: 10.3390/ijms27052179 · International Journal of Molecular Sciences · 2026-02-26

## TL;DR

This study explores how ergothioneine may reduce neuroinflammation by targeting key proteins and pathways, using computational and experimental methods.

## Contribution

The study provides a multi-omics and experimental validation of ergothioneine's anti-inflammatory mechanisms in neuroinflammation.

## Key findings

- EGT targets TNF, AKT1, CASP3, and IL-6 to regulate inflammation pathways.
- In vitro experiments showed EGT reduces pro-inflammatory cytokines in microglia cells.
- Molecular simulations confirmed stable binding between EGT and its targets.

## Abstract

Neuroinflammation is a critical pathological process implicated in several neurological disorders. It arises from complex interactions among immune cells and the excessive release of pro-inflammatory mediators, ultimately leading to neuronal damage. Ergothioneine (EGT), a naturally occurring antioxidant, has attracted attention for its potential anti-inflammatory role in neuroinflammation, although it remains poorly understood. We employed a comprehensive strategy combining network pharmacology, molecular docking, molecular dynamics simulations, and in vitro experiments to explore how EGT influences neuroinflammatory pathways. Computational analyses indicated that EGT might regulate several inflammation-related signaling cascades by targeting key molecules such as Tumor Necrosis Factor (TNF), AKT Serine/Threonine Kinase 1 (AKT1), Caspase 3 (CASP3), and Interleukin 6 (IL-6). Docking and dynamics simulations confirmed strong and stable binding between EGT and these targets. Experiments using lipopolysaccharide-stimulated BV2 microglia cells demonstrated that EGT significantly reduced pro-inflammatory cytokine production, primarily through modulation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways. By integrating multi-omics approaches with cellular validation, this study sheds light on the molecular mechanisms underlying EGT’s anti-inflammatory effect and supports its potential application as a functional food ingredient for managing neuroinflammation.

## Linked entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], CASP3 (caspase 3) [NCBI Gene 836], IL6 (interleukin 6) [NCBI Gene 3569]
- **Proteins:** Casp3 (caspase 3), IL6 (interleukin 6)
- **Chemicals:** Ergothioneine (PubChem CID 5351619)

## Full-text entities

- **Genes:** Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}
- **Diseases:** neuronal damage (MESH:D009410), inflammation (MESH:D007249), neurological disorders (MESH:D009461), Neuroinflammation (MESH:D000090862)
- **Chemicals:** lipopolysaccharide (MESH:D008070), EGT (MESH:D004880)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12985181/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12985181/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12985181/full.md

---
Source: https://tomesphere.com/paper/PMC12985181